Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

Lancet

Volumn 350, Issue 9077, 1997, Pages 550-555

  Lindsay, Robert ^a,b   Nieves, Jeri ^a,b   Formica, Carmelo ^a   Henneman, Emily ^a   Woelfert, Lillian ^a   Shen, Victor ^a,b   Dempster, David ^a,b   Cosman, Felicia ^a,b  

^a HELEN HAYES HOSPITAL   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANABOLIC AGENT; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; FEMALE; HORMONE SUBSTITUTION; HUMAN; LUMBAR VERTEBRA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VERTEBRA FRACTURE;

EID: 0030804947     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)02342-8     Document Type: Article

References (27)

1. Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993; 341: 797-801.
2. Gallagher JC. Estrogen: prevention and treatment of osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press, 1996: 1191-208.
3. Lieberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-33.
4. Overgaard K, Riis BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 1989; 30: 435-42.
5. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992; 305: 1124-28.
6. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-09.
7. Pak CYC, Sakhaee K, Piziak V, et al. Slow release sodium fluoride in the management of postmenopausal osteoporosis. Ann Intern Med 1994; 120: 625-32.
8. Libanati C, Lau KW, Baylink D. Fluoride therapy for osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press, 1996: 1259-77.
9. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14: 690-709.
10. Komar L, Nieves J, Cosman F. Calcium homeostasis of an elderly population upon admission to a nursing home. J Am Geriatr Soc 1993; 41: 1057-64.
11. Cosman F, Nieves J, Horton J, Shen V, Lindsay R. Effects of estrogen on response to EDTA infusion in postmenopausal osteoporotic women. J Clin Endocrinol Metab 1994; 78: 939-43.
12. Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT Jr, Bloch KF. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 1972; 51: 2331-38.
13. Cosman F, Morgan DC, Nieves JW, et al. Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 1997; 12: 958-66.
14. National Osteoporosis Foundation Working Group on Vertebral Fractures. Report: assessing vertebral fractures. J Bone Miner Res 1995; 10: 518-23.
15. Riggs BL, Seeman E, Hodgson SF, et al. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: comparison with conventional therapy. N Engl J Med 1982; 306: 446-50.
16. Kleerekoper M, Parfitt AM, Ellis BI. Measurement of vertebral fracture rates in osteoporosis. In: Osteoporosis I: proceedings of the Copenhagen International Symposium on Osteoporosis. 1984; 103-09.
17. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the replacement of bone loss induced by estrogen deficiency. N Engl J Med 1994; 331: 1618-23.
18. Reeve J, Davies UM, Hesp R, McNally E, Katz D. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. BMJ 1990; 301: 314-18.
19. Neer M, Slovik DM, Daly N, Potts JTJ, Nussbaum SR. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporos Int 1993; 1 (suppl): 204-05.
20. Black DM, Cummings SR, Thompson D, Alendronate reduces the risk of vertebral and clinical fractures in women with existing vertebral fractures: results of the fracture intervention trial. J Bone Miner Res 1996; 11: S151.
21. Parisien M, Silverberg S, Shane E, Dempster DW. Bone disease in primary hyperparathroidism. Endocrinol Metab Clin N Am 1990; 19: 19-34.
22. Hodsman AB, Fraher LJ, Ostbye T, Adachie JD, Steer BM. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 1993; 91: 1138-48.
23. Hodsman AB, Steer BM, Fraher LJ, Drost DJ. Bone densitometric and histomorphometric responses to sequential human parathyroid (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner 1991; 14: 68-83.
24. Jerome CP, Johnson CS, Lees CJ. Effect of treatment for 3 months with human parathyroid hormone 1-34 peptide in ovariectomized cynomolgus monkeys (macaca fascicularis) 1995; 17 (suppl): 4158-205.
25. Meng XW, Liang XG, Birchman R, et al. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res 1996; 11: 421-30.
26. Reeve J, Bradbeer JN, Arlot M, et al. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int 1991; 1: 162-70.
27. Hock JM, Hummer T, Boyce R, Fonseca J, Raisz LG. Resorption is not essential for the stimulation of bone growth by hPTH-(l-34) in rats in vivo. J Bone Miner Res 1989; 4: 449-58.